Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) dropped 3.7% during trading on Tuesday . The stock traded as low as $12.07 and last traded at $12.07. Approximately 227 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 33,381 shares. The stock had previously closed at $12.54.
Finch Therapeutics Group Stock Performance
The business’s 50 day moving average price is $6.75 and its 200-day moving average price is $3.70. The company has a market cap of $18.73 million, a price-to-earnings ratio of -1.15 and a beta of 1.25.
Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($3.01) EPS for the quarter.
Hedge Funds Weigh In On Finch Therapeutics Group
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Read More
- Five stocks we like better than Finch Therapeutics Group
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Leveraged ETFs to Multiply Returns
- Why Are These Companies Considered Blue Chips?
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- ETF Screener: Uses and Step-by-Step Guide
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.